Hepatitis C and double-hit B cell lymphoma successfully treated by antiviral therapy

作     者：Giovanni Galati Lorenzo Rampa Umberto Vespasiani-Gentilucci Mirella Marino Francesco Pisani Carlo Cota Alessandro Guidi Antonio Picardi 

作者机构：Unit of Internal Medicine and Hepatology Department of Medicine Università Campus Bio-Medico di Roma Department of Pathology Regina Elena National Cancer Institute Hematology and Stem Cell Transplant Unit Regina Elena National Cancer Institute Dermopahology Unit San Gallicano Dermatological Institute IRCCS 

出 版 物：《World Journal of Hepatology》 (世界肝病学杂志（英文版）（电子版）)

年 卷 期：2016年第8卷第29期

页      面：1244-1250页

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

主　　题：Hepatitis C Lymphoma Direct antiviral agents Double hit lymphoma Chronic hepatitis C 

摘      要：B cells lymphoma is one of the most challenging extrahepatic manifestations of hepatitis C virus(HCV). Recently, a new kind of B-cell lymphoma, named doublehit B(DHL), was characterized with an aggressive clinical course whereas a potential association with HCV was not investigated. The new antiviral direct agents(DAAs) against HCV are effective and curative in the majority of HCV infections. We report the first case, to our knowledge, of DHL and HCV-infection successfully treated by new DAAs. According to our experience, a DHL must be suspected in case of HCV-related lymphoma, and an early diagnosis could direct towards a different hematological management because a worse prognosis might be expected. A possible effect of DAAs on DHL regression should be investigated, but eradicating HCV would avoid life-threatening reactivation of viral hepatitis during pharmacological immunosuppression in oncohaematological diseases.